Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients

Giorgio Gatti, Pietro Papa, Donato Torre, Massimo Andreoni, Antonio Poggio, Matteo Bassetti, Piero Marone

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Rifabutin pharmacokinetics were studied by the population approach (NONMEM) with 40 human immunodeficiency virus-infected patients receiving rifabutin at different doses for prophylaxis or therapy of mycobacterial infections. A two-compartment open model with first-order absorption was used as the structural pharmacokinetic model. Parameter estimates were the absorption rate constant (0.201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (V(p)/F; 1,050 liters). The distribution and elimination half-lives were 1.24 and 25.4 h, respectively. The covariates tested for influence on CL/F and V(p)/F were sex, age, weight, height, body surface area, tobacco smoking, drug addiction, alanine aminotransferase levels, creatinine clearance, total protein, bilirubin, numbers of CD4+ cells, presence of diarrhea, cachexia index, rifabutin use (prophylaxis versus therapy), rifabutin dose, study site, and the concomitant administration of clarithromycin, fluconazole, phenobarbital, ciprofloxacin, azithromycin, or benzodiazepines. The only statistically significant effects on rifabutin pharmacokinetic parameters were a 27% decrease in V(p)/F due to the concomitant administration of azithromycin and a 39% increase in V(p)/F due to tobacco smoking. Such effects may be considered clinically unimportant. Our results confirm the lack of a correlation of rifabutin pharmacokinetic parameters with parameters of disease progression and gastrointestinal function. Also, the lack of a correlation with covariates which were previously found to be significant, such as concomitant fluconazole and clarithromycin use, may suggest that the effect of such covariates may be less important in the real clinical setting, in which several concomitant factors may influence pharmacokinetic parameters, with an overall effect of no apparent correlation.

Original languageEnglish
Pages (from-to)2017-2023
Number of pages7
JournalAntimicrobial Agents and Chemotherapy
Volume42
Issue number8
Publication statusPublished - Aug 1998

Fingerprint

Rifabutin
Pharmacokinetics
HIV
Population
Biological Availability
Azithromycin
Clarithromycin
Fluconazole
Smoking
Cachexia
Body Surface Area
Structural Models
Phenobarbital
Ciprofloxacin
Alanine Transaminase
Benzodiazepines
Bilirubin
Substance-Related Disorders
Disease Progression
Diarrhea

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. / Gatti, Giorgio; Papa, Pietro; Torre, Donato; Andreoni, Massimo; Poggio, Antonio; Bassetti, Matteo; Marone, Piero.

In: Antimicrobial Agents and Chemotherapy, Vol. 42, No. 8, 08.1998, p. 2017-2023.

Research output: Contribution to journalArticle

Gatti, Giorgio ; Papa, Pietro ; Torre, Donato ; Andreoni, Massimo ; Poggio, Antonio ; Bassetti, Matteo ; Marone, Piero. / Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients. In: Antimicrobial Agents and Chemotherapy. 1998 ; Vol. 42, No. 8. pp. 2017-2023.
@article{f5a091774a8e488c92eab321477cb35f,
title = "Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients",
abstract = "Rifabutin pharmacokinetics were studied by the population approach (NONMEM) with 40 human immunodeficiency virus-infected patients receiving rifabutin at different doses for prophylaxis or therapy of mycobacterial infections. A two-compartment open model with first-order absorption was used as the structural pharmacokinetic model. Parameter estimates were the absorption rate constant (0.201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (V(p)/F; 1,050 liters). The distribution and elimination half-lives were 1.24 and 25.4 h, respectively. The covariates tested for influence on CL/F and V(p)/F were sex, age, weight, height, body surface area, tobacco smoking, drug addiction, alanine aminotransferase levels, creatinine clearance, total protein, bilirubin, numbers of CD4+ cells, presence of diarrhea, cachexia index, rifabutin use (prophylaxis versus therapy), rifabutin dose, study site, and the concomitant administration of clarithromycin, fluconazole, phenobarbital, ciprofloxacin, azithromycin, or benzodiazepines. The only statistically significant effects on rifabutin pharmacokinetic parameters were a 27{\%} decrease in V(p)/F due to the concomitant administration of azithromycin and a 39{\%} increase in V(p)/F due to tobacco smoking. Such effects may be considered clinically unimportant. Our results confirm the lack of a correlation of rifabutin pharmacokinetic parameters with parameters of disease progression and gastrointestinal function. Also, the lack of a correlation with covariates which were previously found to be significant, such as concomitant fluconazole and clarithromycin use, may suggest that the effect of such covariates may be less important in the real clinical setting, in which several concomitant factors may influence pharmacokinetic parameters, with an overall effect of no apparent correlation.",
author = "Giorgio Gatti and Pietro Papa and Donato Torre and Massimo Andreoni and Antonio Poggio and Matteo Bassetti and Piero Marone",
year = "1998",
month = "8",
language = "English",
volume = "42",
pages = "2017--2023",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients

AU - Gatti, Giorgio

AU - Papa, Pietro

AU - Torre, Donato

AU - Andreoni, Massimo

AU - Poggio, Antonio

AU - Bassetti, Matteo

AU - Marone, Piero

PY - 1998/8

Y1 - 1998/8

N2 - Rifabutin pharmacokinetics were studied by the population approach (NONMEM) with 40 human immunodeficiency virus-infected patients receiving rifabutin at different doses for prophylaxis or therapy of mycobacterial infections. A two-compartment open model with first-order absorption was used as the structural pharmacokinetic model. Parameter estimates were the absorption rate constant (0.201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (V(p)/F; 1,050 liters). The distribution and elimination half-lives were 1.24 and 25.4 h, respectively. The covariates tested for influence on CL/F and V(p)/F were sex, age, weight, height, body surface area, tobacco smoking, drug addiction, alanine aminotransferase levels, creatinine clearance, total protein, bilirubin, numbers of CD4+ cells, presence of diarrhea, cachexia index, rifabutin use (prophylaxis versus therapy), rifabutin dose, study site, and the concomitant administration of clarithromycin, fluconazole, phenobarbital, ciprofloxacin, azithromycin, or benzodiazepines. The only statistically significant effects on rifabutin pharmacokinetic parameters were a 27% decrease in V(p)/F due to the concomitant administration of azithromycin and a 39% increase in V(p)/F due to tobacco smoking. Such effects may be considered clinically unimportant. Our results confirm the lack of a correlation of rifabutin pharmacokinetic parameters with parameters of disease progression and gastrointestinal function. Also, the lack of a correlation with covariates which were previously found to be significant, such as concomitant fluconazole and clarithromycin use, may suggest that the effect of such covariates may be less important in the real clinical setting, in which several concomitant factors may influence pharmacokinetic parameters, with an overall effect of no apparent correlation.

AB - Rifabutin pharmacokinetics were studied by the population approach (NONMEM) with 40 human immunodeficiency virus-infected patients receiving rifabutin at different doses for prophylaxis or therapy of mycobacterial infections. A two-compartment open model with first-order absorption was used as the structural pharmacokinetic model. Parameter estimates were the absorption rate constant (0.201/h), clearance/bioavailability (CL/F; 60.9 liters/h), volume of the central compartment/bioavailability (231 liters), intercompartmental clearance (60.3 liters/h), and volume of the peripheral compartment/bioavailability (V(p)/F; 1,050 liters). The distribution and elimination half-lives were 1.24 and 25.4 h, respectively. The covariates tested for influence on CL/F and V(p)/F were sex, age, weight, height, body surface area, tobacco smoking, drug addiction, alanine aminotransferase levels, creatinine clearance, total protein, bilirubin, numbers of CD4+ cells, presence of diarrhea, cachexia index, rifabutin use (prophylaxis versus therapy), rifabutin dose, study site, and the concomitant administration of clarithromycin, fluconazole, phenobarbital, ciprofloxacin, azithromycin, or benzodiazepines. The only statistically significant effects on rifabutin pharmacokinetic parameters were a 27% decrease in V(p)/F due to the concomitant administration of azithromycin and a 39% increase in V(p)/F due to tobacco smoking. Such effects may be considered clinically unimportant. Our results confirm the lack of a correlation of rifabutin pharmacokinetic parameters with parameters of disease progression and gastrointestinal function. Also, the lack of a correlation with covariates which were previously found to be significant, such as concomitant fluconazole and clarithromycin use, may suggest that the effect of such covariates may be less important in the real clinical setting, in which several concomitant factors may influence pharmacokinetic parameters, with an overall effect of no apparent correlation.

UR - http://www.scopus.com/inward/record.url?scp=0031928115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031928115&partnerID=8YFLogxK

M3 - Article

C2 - 9687400

AN - SCOPUS:0031928115

VL - 42

SP - 2017

EP - 2023

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -